Favorable PFS Continues to be Observed With Ibrutinib/Rituximab in CLL
December 8th 2019Updated follow-up analysis of the phase III E1912 study showed that ibrutinib/rituximab induced higher rates of progression-free survival (PFS) when compared against fludarabine, cyclophosphamide, and rituximab in patients ≤70 years with previously untreated chronic lymphocytic leukemia (CLL), according to Tait D. Shanafelt, MD, who presented the findings at the 2019 ASH Annual Meeting.
Read More
Undetectable MRD Is Reached in Patients With CLL Receiving First-Line Ibrutinib/Venetoclax
December 8th 2019Patients <70 years old with chronic lymphocytic leukemia treated in the minimal residual disease (MRD)–cohort of the phase II CAPTIVATE trial had undetectable MRD rates of 75% and 72% in the peripheral blood and bone marrow, respectively, with the frontline combination of ibrutinib and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Read More
Three-Year Overall Survival Data Reported for Axi-Cel in B-Cell Lymphoma
December 8th 2019Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial.
Read More
Durable Complete Remissions Achieved in NHL Following CAR T
December 8th 2019Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
Read More
Patients With CLL Treated on the ELEVATE-TN Trial Experience Improved PFS With Acalabrutinib
December 8th 2019Patients with treatment-naïve chronic lymphocytic leukemia experienced a statistically significant improvement in progression-free survival with acalabrutinib as a single agent or in combination with obinutuzumab when compared with obinutuzumab plus chlorambucil, according to results from the phase III ELEVATE-TN trial presented at the 2019 ASH Annual Meeting.
Read More
Encouraging signs of dose-dependent efficacy, as well as a promising safety profile, were observed in patients with heavily pretreated relapsed/refractory multiple myeloma who were treated with CC-93269, a human IgG1-based T-cell engager that binds to BCMA and CD3 epsilon in a 2+1 format.
Read More
CAR T-Cell Therapy Targeting BCMA and CD38 Induces Positive Responses in Multiple Myeloma
December 8th 2019Patients with a difficult-to-treat form of multiple myeloma who were treated with a novel, bispecific anti-BCMA/anti-CD38 chimeric antigen receptor (CAR) T-cell therapy experienced promising responses and a manageable safety profile, according to results of a study that were presented at the 61st Annual American Society of Hematology Annual Meeting and Exposition.<br />
Read More
Preclinical Evidence Generates Buzz Around Novel Off-the-Shelf CAR NK Therapy
December 7th 2019A multi-antigen off-the-shelf chimeric antigen receptor natural killer cell therapy has been included in the ASH annual meeting spotlight due to exciting preclinical evidence. An investigational new drug application was approved in September 2019 for the therapy, labeled as FT596, developed by Fate Therapeutics, and human trials are scheduled to start in the first quater of 2020.
Read More
Triplet Regimen Could Replace Standard of Care for Transplant-Ineligible Myeloma
December 5th 2018According to the phase III MAIA trial, triplet regimen daratumumab, lenalidomide, plus dexamethasone reduced risk of disease progression or death by 44% in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant, compared to patients who received lenalidomide plus dexamethasone.
Read More
Selinexor Combo Sees Activity in Heavily Pretreated Penta-Refractory Myeloma
December 5th 2018An overall response rate of 26.2% was induced by selinexor, an oral XPO1 inhibitor, combination in heavily pretreated patients with penta-refractory multiple myeloma. According to the findings from part 2 of the pivotal STORM trial, selinexor is now the first investigational oral therapy to show activity in these patients.
Read More
Consistent OS Benefit Seen Across Patient Subgroups With Quizartinib in AML
December 5th 2018An update on the pivotal phase III QuANTUM-R study presented at the 2018 ASH Annual Meeting demonstrated overall survival benefit across patient subgroups with quizartinib in patients with relapsed/refractory <em>FLT3</em>-ITD–mutated acute myeloid leukemia.
Read More
Risk of Progression Significantly Reduced With Upfront Ibrutinib and Obinutuzumab in CLL/SLL
December 4th 2018A significant reduction in the risk of disease progression or death was observed from treatment with the upfront combination of ibrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with chlorambucil and obinutuzumab.
Read More
Durable Responses Achieved With Acalabrutinib in MCL
December 4th 2018Durable responses were achieved with acalabrutinib therapy for patients with relapsed/refractory mantle cell lymphoma, with 40% still on treatment for more than 2 years, according to long-term follow-up findings presented at the 2018 ASH Annual Meeting.
Read More
Early Activity Seen With Anti-BCMA CAR T Cell in Heavily Pretreated Multiple Myeloma
December 4th 2018Initial results from a phase I study showed an objective response rate of 83.3% had been achieved in heavily pretreated patients with relapsed/refractory multiple myeloma who had been treated with the anti-BCMA CAR T-cell therapy bb21217.
Read More
Key Findings Reviewed From ALCYONE Trial in Myeloma
December 4th 2018Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib, melphalan, and prednisone in combination with daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible.
Read More
Promising Results Seen With Ibrutinib Plus Venetoclax Combo in Relapsed/Refractory CLL
December 3rd 2018According to a presentation of findings from the phase II CLARITY study at the 2018 ASH Annual Meeting, ibrutinib in combination with venetoclax demonstrated tolerability among patients with relapsed/refractory chronic lymphocytic leukemia. The combination also induced minimal residual disease negativity in the marrow in 39% of these patients after 12 months.
Read More
Findings Support Venetoclax Plus HMAs for Patients With AML Ineligible for Intensive Chemo
December 3rd 2018Among older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy, preliminary findings demonstrated that more than 70% achieved complete responses to venetoclax in combination with hypomethylating agents.
Read More
Two-Year Ixazomib Maintenance Delayed Progression in Newly Diagnosed Myeloma
December 3rd 2018According to findings from the phase III TOURMALINE-MM3, a 39% improvement in progression-free survival was demonstrated with 2-year maintenance therapy with ixazomib compared with placebo for patients with newly diagnosed multiple myeloma who had previously achieved a partial response with an induction therapy of a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.
Read More
Promising Findings for Daratumumab Plus VRd in Multiple Myeloma
December 3rd 2018Peter M. Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses efficacy and updated safety findings of a safety run-in cohort from the phase II Griffin trial, a randomized study of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-Vrd) versus Vrd in patients with newly diagnosed multiple myeloma eligible for high-dose therapy and autologous stem cell transplantation, during the 2018 ASH Annual Meeting.
Read More
Rapid AML Subtype Assessment Possible at Diagnosis, Collaborative Trial Shows
December 3rd 2018It may be possible for hematologists to determine subtypes of acute myeloid leukemia based on genetic analsysis of blood samples in 7 days or less. According to Amy Burd, PhD, this process could play an important role in diagnosing and treating patients.
Read More
Triplet Regimen Induced 90% Response Rate in Patients With CLL
December 3rd 2018Pembrolizumab in combination with umbralisib and ublituximab induced responses in 90% of patients with relapsed/refractory chronic lymphocytic leukemia, according to data from a phase I/II study presented at the 2018 ASH Annual Meeting. Additionally, a 50% response rate was also demonstrated in patients with Richter’s transformation.
Read More
Efficacy of Ibrutinib in CLL/SLL Upheld at 7-Year Follow-Up
December 3rd 2018After 7 years of follow-up, single-agent ibrutinib demonstrated continued efficacy in the frontline and heavily pretreated, relapsed/refractory settings for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
High Response Rate Found in Heavily Pretreated, High-Risk CLL With Liso-Cel
December 3rd 2018Lisocabtagene maraleucel induced an 81.3% best overall response rate and 43.8% complete response in high-risk patients with chronic lymphocytic leukemia who were heavily pretreated and had previously received ibrutinib, according to dose-finding results presented at the 2018 ASH Annual Meeting.
Read More
High Response Rate Found in Relapsed/Refractory MCL With Zanubrutinib
December 3rd 2018Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of a phase II trial.<br />
Read More
I-O Combo of Checkpoint Inhibitor With CAR T-Cell Therapy Shows Promise in Relapsed B-Cell ALL
December 3rd 2018According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Read More
Daratumumab With VRd Induced VGPR in 100% of Patients With Multiple Myeloma
December 3rd 2018In a study of transplant-eligible patients with newly diagnosed multiple myeloma, daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients, including a complete response in 63% of patients, at the end of consolidation therapy.<br />
Read More
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALL
December 2nd 2018Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
Read More
High Response Rate Found in CLL With Ibrutinib/CAR T-Cell Combo
December 2nd 2018According to a retrospective phase I/II study, over 80% of patients with relapsed or refractory chronic lymphocytic leukemia responded to concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor CAR T-cell therapy, JCAR014.<sup>1</sup> Findings from this study were presented at the 60th American Society of Hematology Annual Meeting.
Read More
Need for RBC Transfusion Reduced With Novel Agent for Low-Risk MDS-Related Anemia
December 2nd 2018The need for frequent red blood cell transfusions was reduced with luspatercept in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.
Read More